Mission Therapeutics Ltd. CEO Anker Lundemose speaks to Scrip senior editor Lucie Ellis about the company's clinical strategy that will see its first compound enter human trials in the first half 2019.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?